Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience

In randomized clinical trials (RCTs) proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors showed a favorable safety profile, however, “real‐world” data on adverse events (AEs) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and Vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gürgöze, Muhammed T., Muller‐Hansma, Annemarie H.G., Schreuder, Michelle M., Galema‐Boers, Annette M.H., Boersma, Eric, Roeters van Lennep, Jeanine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704355/
https://www.ncbi.nlm.nih.gov/pubmed/30053327
http://dx.doi.org/10.1002/cpt.1193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704355/
https://www.ncbi.nlm.nih.gov/pubmed/30053327
http://dx.doi.org/10.1002/cpt.1193

Ejemplares similares